Telatinib
- Generic Name
- Telatinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H16ClN5O3
- CAS Number
- 332012-40-5
- Unique Ingredient Identifier
- 18P7197Q7J
- Background
Telatinib is under investigation in clinical trial NCT03817411 (Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma
Phase 2
Active, not recruiting
- Conditions
- Gastric CancerHepatocellular Carcinoma
- Interventions
- Drug: TelatinibDrug: Keytruda
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Andrew Hendifar, MD
- Target Recruit Count
- 16
- Registration Number
- NCT04798781
- Locations
- 🇺🇸
CS Cancer at The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸CS Cancer at the Samuel Oschin Cancer Center, Los Angeles, California, United States
🇺🇸CS Cancer Beverly Hills, Beverly Hills, California, United States
Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer
Phase 2
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- Taizhou EOC Pharma Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT03817411
- Locations
- 🇨🇳
Shanghai Easter Hospital, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath